# Xyla, 20 mg/ml solution for injection for cattle, horses, dogs and cats

Authorised

- Xylazine hydrochloride

## Product identification

**Medicine name:**
Xyla, 20 mg/ml solution for injection for cattle, horses, dogs and cats
Sedachem 20 mg/ml injektionsvæske, opløsning

**Active substance:**
Xylazine hydrochloride

**Target species:**
Cattle
Horse
Dog
Cat

**Route of administration:**
Intravenous use
Intramuscular use
Subcutaneous use

## Product details

**Active substance and strength:**
Xylazine hydrochloride
23.32 milligram(s) / 1.00 millilitre(s)

---

**Pharmaceutical form:**
Solution for injection

---

**Withdrawal period by route of administration:**
**Intravenous use:**

- **Cattle**
  - Meat and offal. 1 day
  - Milk. 0 hour
- **Horse**
  - Meat and offal. 1 day
  - Milk. 0 hour

**Intramuscular use:**

- **Cattle**
  - Meat and offal. 1 day
  - Milk. 0 hour

---

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**
QN05CM92

---

**Legal status of supply:**
Veterinary medicinal product subject to veterinary prescription

---

**Authorisation status:**
Valid

---

**Authorised in:**
Denmark

**Package description:**
50 ml clear, type II glass bottle, closed with a bromobutyl rubber stopper and secured with an aluminium cap. Package size: 5x50 ml in a cardboard box.
50 ml clear, type II glass bottle, closed with a bromobutyl rubber stopper and secured with an aluminium cap. Package size: 1x50 ml in a cardboard box.

## Additional information

**Entitlement type:**
Marketing Authorisation

**Legal basis of product authorisation:**
Generic application (Article 13(1) of Directive No 2001/82/EC)

**Marketing authorisation holder:**
Interchemie Werken De Adelaar Eesti AS

**Marketing authorisation date:**
27/11/2020

**Manufacturing sites for batch release:**
Interchemie Werken De Adelaar Eesti AS

**Responsible authority:**
Danish Medicines Agency

**Authorisation number:**
64593

**Date of authorisation status change:**
27/11/2020

**Reference member state:**
Estonia

**Procedure number:**

EE/V/0105/001

**Concerned member states:**
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

## Documents

Summary of Product Characteristics

English (PDF)
Published on: 31/07/2025
Download